Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
In patients with histologically confirmed prostate cancer, oestrogen priming with diethylstilboestrol (DES) (3 mg/day) for 4 weeks prior to the first injection of the LHRH agonist Zoladex (3.6 mg depot form) prevented any rise in the serum testosterone concentration. In contrast, in the groups pre-treated with DES, the first, but not subsequent, injections with Zoladex were associated with a marked surge in luteinising hormone. Treatment with DES beyond the time of the first administration of Zoladex did not provide further endocrinological advantage. Oestrogen priming for 1 month prior to treatment with Zoladex may prevent an exacerbation of signs and symptoms of prostate cancer.
Kreis
W
W
Department of Medicine, North Shore University Hospital, Cornell University Medical College, Manhasset, NY.
Ahmann
F R
FR
Jordan
V C
VC
de Haan
H
H
Scott
M
M
D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004054:Diethylstilbestrol / Q000627:therapeutic use*; D017273:Goserelin; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013739:Testosterone / Q000097:blood*
D017273:Goserelin; D013739:Testosterone; D004054:Diethylstilbestrol; D007986:Luteinizing Hormone; D002064:Buserelin